First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
ConclusionsA 24-week pioglitazone treatment was well-tolerated and effective in improving liver histology and reducing liver steatosis in Asian NASH patients. (ClinicalTrials.gov number: NCT01068444)
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Actos | Alcoholism | Infectious Diseases | Insulin | Liver | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology